QCI Asset Management’s BioNTech BNTX Stock Holding History

QCI Asset Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-75	Closed	-$4K	–	174
2020 Q1	$4K	Hold	75	–	–	﹤0.01%	474
2019 Q4	$3K	Buy	+75	New	+$1.68K	﹤0.01%	522

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

QCI Asset Management's BNTX Position: Q2 2020 in Review

QCI Asset Management sold out of BioNTech (BNTX) in Q2 2020, closing a stake of 75 shares — an estimated $4K sold.

QCI Asset Management first reported a position in BNTX in Q4 2019 and held it in 2 quarters. The position peaked at $4K in Q1 2020. 109 funds tracked by Wall St. Rank hold BNTX as of Q2 2020.

QCI Asset Management reported no remaining BioNTech position as of Q2 2020 after selling out during the quarter.
QCI Asset Management sold 75 BioNTech shares in Q2 2020, an estimated $4K.
QCI Asset Management first reported a position in BioNTech in Q4 2019 and held it in 2 quarters.
QCI Asset Management's BioNTech position peaked at $4K in Q1 2020.
109 funds tracked by Wall St. Rank held BioNTech as of Q2 2020.

Based on QCI Asset Management's 13F filing for Q2 2020, filed 31 Jul 2020.